Risk of arterial thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: An up-to-date meta-analysis
- 1 November 2014
- journal article
- research article
- Published by Elsevier BV in Critical Reviews in Oncology/Hematology
- Vol. 92 (2), 71-82
- https://doi.org/10.1016/j.critrevonc.2014.04.004
Abstract
No abstract availableKeywords
This publication has 62 references indexed in Scilit:
- Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trialThe Lancet, 2012
- Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III TrialJournal of Clinical Oncology, 2012
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III TrialJournal of Clinical Oncology, 2010
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Activity of Sunitinib in Patients With Advanced Neuroendocrine TumorsJournal of Clinical Oncology, 2008
- Sunitinib versus Interferon Alfa in Metastatic Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trialThe Lancet, 2006
- Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and AngiogenesisJournal of Clinical Oncology, 2005
- Anti-AngiogenesisAnnals of Surgery, 1972